Eosinophilia Is a Favorable Marker for Pneumonia in Chronic Obstructive Pulmonary Disease.

IF 2.5 Q2 RESPIRATORY SYSTEM
Tuberculosis and Respiratory Diseases Pub Date : 2024-10-01 Epub Date: 2024-05-03 DOI:10.4046/trd.2023.0174
Kang-Mo Gu, Jae-Woo Jung, Min-Jong Kang, Deog Kyeom Kim, Hayoung Choi, Young-Jae Cho, Seung Hun Jang, Chang-Hoon Lee, Yeon Mok Oh, Ji Sook Park, Jae Yeol Kim
{"title":"Eosinophilia Is a Favorable Marker for Pneumonia in Chronic Obstructive Pulmonary Disease.","authors":"Kang-Mo Gu, Jae-Woo Jung, Min-Jong Kang, Deog Kyeom Kim, Hayoung Choi, Young-Jae Cho, Seung Hun Jang, Chang-Hoon Lee, Yeon Mok Oh, Ji Sook Park, Jae Yeol Kim","doi":"10.4046/trd.2023.0174","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients with chronic obstructive pulmonary disease (COPD) expressing eosinophilia experience slightly fewer episodes of community-acquired pneumonia (CAP), than those without eosinophilia. However, the severity and burden of hospitalized pneumonia patients with COPD involving eosinophilia have not been assessed.</p><p><strong>Methods: </strong>We evaluated the differences in clinical characteristics between patients with CAP and COPD with or without eosinophilia by a post hoc analysis of a prospective, multi-center, cohort study data.</p><p><strong>Results: </strong>Of 349 CAP patients with COPD, 45 (12.9%) had eosinophilia (blood eosinophil ≥300 cells/μL). Patients with eosinophilia had a lower sputum culture percentile (8.1% vs. 23.4%, p&lt;0.05), a lower percentile of neutrophils (70.3% vs. 80.2%, p&lt;0.05), reduced C-reactive protein levels (30.6 mg/L vs. 86.6 mg/L, p&lt;0.05), and a lower pneumonia severity index score (82.5 vs. 90.0, p&lt;0.05), than those without eosinophilia. The duration of antibiotic treatment (8.0 days vs. 10.0 days, p&lt;0.05) and hospitalization (7.0 days vs. 9.0 days, p&lt;0.05) were shorter in eosinophilic patients. The cost of medical care per day (256.4 US$ vs. 291.0 US$, p&lt;0.05), cost for the medication (276.4 US$ vs. 349.9 US$, p&lt;0.05), and cost for examination (685.5 US$ vs. 958.1 US$, p&lt;0.05) were lower in patients with eosinophilia than those without eosinophilia.</p><p><strong>Conclusion: </strong>Eosinophilia serves as a favorable marker for the severity of pneumonia, health-care consumption, and cost of medical care in patients with CAP and COPD.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11468446/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberculosis and Respiratory Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4046/trd.2023.0174","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Patients with chronic obstructive pulmonary disease (COPD) expressing eosinophilia experience slightly fewer episodes of community-acquired pneumonia (CAP), than those without eosinophilia. However, the severity and burden of hospitalized pneumonia patients with COPD involving eosinophilia have not been assessed.

Methods: We evaluated the differences in clinical characteristics between patients with CAP and COPD with or without eosinophilia by a post hoc analysis of a prospective, multi-center, cohort study data.

Results: Of 349 CAP patients with COPD, 45 (12.9%) had eosinophilia (blood eosinophil ≥300 cells/μL). Patients with eosinophilia had a lower sputum culture percentile (8.1% vs. 23.4%, p<0.05), a lower percentile of neutrophils (70.3% vs. 80.2%, p<0.05), reduced C-reactive protein levels (30.6 mg/L vs. 86.6 mg/L, p<0.05), and a lower pneumonia severity index score (82.5 vs. 90.0, p<0.05), than those without eosinophilia. The duration of antibiotic treatment (8.0 days vs. 10.0 days, p<0.05) and hospitalization (7.0 days vs. 9.0 days, p<0.05) were shorter in eosinophilic patients. The cost of medical care per day (256.4 US$ vs. 291.0 US$, p<0.05), cost for the medication (276.4 US$ vs. 349.9 US$, p<0.05), and cost for examination (685.5 US$ vs. 958.1 US$, p<0.05) were lower in patients with eosinophilia than those without eosinophilia.

Conclusion: Eosinophilia serves as a favorable marker for the severity of pneumonia, health-care consumption, and cost of medical care in patients with CAP and COPD.

嗜酸性粒细胞增多是慢性阻塞性肺病肺炎的一个有利标志。
背景:嗜酸性粒细胞增多的慢性阻塞性肺病(COPD)患者发生社区获得性肺炎(CAP)的次数略少于无嗜酸性粒细胞增多的患者。然而,尚未对嗜酸性粒细胞增多症 COPD 患者住院肺炎的严重程度和负担进行评估:我们通过对一项前瞻性、多中心、队列研究数据进行事后分析,评估了有或无嗜酸性粒细胞增多症的 CAP 和 COPD 患者的临床特征差异:在 349 名患有慢性阻塞性肺病的 CAP 患者中,有 45 人(12.9%)患有嗜酸性粒细胞增多症(血液中嗜酸性粒细胞≥ 300 cells/µL)。嗜酸性粒细胞增多症患者的痰培养百分位数较低(8.1% vs. 23.4%,P < 0.05),中性粒细胞百分位数较低(70.3% vs. 80.2%,PC结论:嗜酸性粒细胞增多是CAP和慢性阻塞性肺病患者肺炎严重程度、医疗消耗和医疗费用的有利指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.30
自引率
0.00%
发文量
42
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信